Gain Therapeutics Ownership 2024 | Who Owns Gain Therapeutics Now?


OverviewForecastRevenueFinancialsChart

Institutional Ownership

4.56%

Insider Ownership

5.09%

Retail Ownership

90.34%

Institutional Holders

8.00

Gain Therapeutics Institutional Shareholders


Institutional Shareholders by % of Total Shares

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
TIMELO INVESTMENT MANAGEMENT INC.3.37%0.44%605,288605,288100.00%774,769Jun 30, 2024
DME CAPITAL MANAGEMENT, LP3.15%0.04%566,130--724,646Jun 30, 2024
ALYESKA INVESTMENT GROUP, L.P.2.50%0.00%450,000450,000100.00%576,000Jun 30, 2024
HOHIMER WEALTH MANAGEMENT, LLC1.84%0.10%330,000330,000100.00%422,400Jun 30, 2024
GEODE CAPITAL MANAGEMENT, LLC1.02%-183,7366,6453.75%235,217Jun 30, 2024
VANGUARD GROUP INC0.81%-145,21725,85321.66%185,878Jun 30, 2024
CABLE CAR CAPITAL LLC0.81%0.20%145,000145,000100.00%185,600Jun 30, 2024
RENAISSANCE TECHNOLOGIES LLC0.66%0.00%118,70072,000154.18%151,936Jun 30, 2024
CM MANAGEMENT, LLC0.50%0.11%90,000--115,200Jun 30, 2024
BLACKROCK INC.0.47%-84,6209,22212.23%108,313Jun 30, 2024
WARBERG ASSET MANAGEMENT LLC0.29%0.01%51,60051,600100.00%65,532Jun 30, 2024
NORTHERN TRUST CORP0.25%-44,944-1,542-3.32%57,529,000Jun 30, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC0.22%0.00%40,00010,00033.33%51,200Jun 30, 2024
PRELUDE CAPITAL MANAGEMENT, LLC0.20%0.00%35,820--45,850Jun 30, 2024
STATE STREET CORP0.19%-34,4373,60011.67%44,079,000Jun 30, 2024
VIRTU FINANCIAL LLC0.15%0.00%27,35627,356100.00%35,000Jun 30, 2024
MILLENNIUM MANAGEMENT LLC0.13%-23,373-21,043-47.38%29,917Jun 30, 2024
UBS GROUP AG0.06%-11,4222,74931.70%14,620Jun 30, 2024
GILBERT & COOK, INC.0.06%0.00%10,00010,000100.00%12,800Jun 30, 2024
SIMPLEX TRADING, LLC0.05%-9,059-8,924-49.62%11,000Jun 30, 2024

Gain Therapeutics's largest institutional shareholder is TIMELO INVESTMENT MANAGEMENT INC., holding 3.37% of the company's total share outstanding, currently valued at $774.77K. The top 10 institutional shareholders own together 15.12% of the company.

Institutional Shareholders by % of Total Assets

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
TIMELO INVESTMENT MANAGEMENT INC.3.37%0.44%605,288605,288100.00%774,769Jun 30, 2024
CABLE CAR CAPITAL LLC0.81%0.20%145,000145,000100.00%185,600Jun 30, 2024
CM MANAGEMENT, LLC0.50%0.11%90,000--115,200Jun 30, 2024
HOHIMER WEALTH MANAGEMENT, LLC1.84%0.10%330,000330,000100.00%422,400Jun 30, 2024
DME CAPITAL MANAGEMENT, LP3.15%0.04%566,130--724,646Jun 30, 2024
WARBERG ASSET MANAGEMENT LLC0.29%0.01%51,60051,600100.00%65,532Jun 30, 2024
ALYESKA INVESTMENT GROUP, L.P.2.50%0.00%450,000450,000100.00%576,000Jun 30, 2024
PRELUDE CAPITAL MANAGEMENT, LLC0.20%0.00%35,820--45,850Jun 30, 2024
VIRTU FINANCIAL LLC0.15%0.00%27,35627,356100.00%35,000Jun 30, 2024
GILBERT & COOK, INC.0.06%0.00%10,00010,000100.00%12,800Jun 30, 2024
CREEKMUR ASSET MANAGEMENT LLC0.02%0.00%4,440--5,683Jun 30, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC0.22%0.00%40,00010,00033.33%51,200Jun 30, 2024
RENAISSANCE TECHNOLOGIES LLC0.66%0.00%118,70072,000154.18%151,936Jun 30, 2024
TOWER RESEARCH CAPITAL LLC (TRC)0.01%-1,729-2,903-62.67%2,213Jun 30, 2024
GROUP ONE TRADING, L.P.0.04%-7,4015,400269.87%9,473,000Jun 30, 2024
GEODE CAPITAL MANAGEMENT, LLC1.02%-183,7366,6453.75%235,217Jun 30, 2024
MILLENNIUM MANAGEMENT LLC0.13%-23,373-21,043-47.38%29,917Jun 30, 2024
JONES FINANCIAL COMPANIES LLLP0.04%-7,0007,000100.00%8,960Jun 30, 2024
NORTHERN TRUST CORP0.25%-44,944-1,542-3.32%57,529,000Jun 30, 2024
SIMPLEX TRADING, LLC0.05%-9,059-8,924-49.62%11,000Jun 30, 2024

The largest Gain Therapeutics shareholder by % of total assets is TIMELO INVESTMENT MANAGEMENT INC.. The company owns 605.29K shares of Gain Therapeutics (GANX), representing 0.44% of its total assets.

Institutional Buyers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
TIMELO INVESTMENT MANAGEMENT INC.3.37%0.44%605,288605,288100.00%774,769Jun 30, 2024
ALYESKA INVESTMENT GROUP, L.P.2.50%0.00%450,000450,000100.00%576,000Jun 30, 2024
HOHIMER WEALTH MANAGEMENT, LLC1.84%0.10%330,000330,000100.00%422,400Jun 30, 2024
CABLE CAR CAPITAL LLC0.81%0.20%145,000145,000100.00%185,600Jun 30, 2024
RENAISSANCE TECHNOLOGIES LLC0.66%0.00%118,70072,000154.18%151,936Jun 30, 2024
WARBERG ASSET MANAGEMENT LLC0.29%0.01%51,60051,600100.00%65,532Jun 30, 2024
VIRTU FINANCIAL LLC0.15%0.00%27,35627,356100.00%35,000Jun 30, 2024
VANGUARD GROUP INC0.81%-145,21725,85321.66%185,878Jun 30, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC0.22%0.00%40,00010,00033.33%51,200Jun 30, 2024
GILBERT & COOK, INC.0.06%0.00%10,00010,000100.00%12,800Jun 30, 2024
BLACKROCK INC.0.47%-84,6209,22212.23%108,313Jun 30, 2024
JONES FINANCIAL COMPANIES LLLP0.04%-7,0007,000100.00%8,960Jun 30, 2024
GEODE CAPITAL MANAGEMENT, LLC1.02%-183,7366,6453.75%235,217Jun 30, 2024
GROUP ONE TRADING, L.P.0.04%-7,4015,400269.87%9,473,000Jun 30, 2024
STATE STREET CORP0.19%-34,4373,60011.67%44,079,000Jun 30, 2024
UBS GROUP AG0.06%-11,4222,74931.70%14,620Jun 30, 2024
MORGAN STANLEY0.02%-3,30050017.86%4,224Jun 30, 2024
BANK OF AMERICA CORP /DE/0.02%-3,5001253.70%4,480Jun 30, 2024
CREEKMUR ASSET MANAGEMENT LLC0.02%0.00%4,440--5,683Jun 30, 2024
PRELUDE CAPITAL MANAGEMENT, LLC0.20%0.00%35,820--45,850Jun 30, 2024

As of Jun 30 2024, Gain Therapeutics's largest institutional buyer is TIMELO INVESTMENT MANAGEMENT INC.. The company purchased 605.29K stocks of GANX, valued at $774.77K.

Institutional Sellers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
RAYMOND JAMES & ASSOCIATES----260,019-100.00%-Jun 30, 2024
ROYAL BANK OF CANADA----248,500-100.00%-Jun 30, 2024
MILLENNIUM MANAGEMENT LLC0.13%-23,373-21,043-47.38%29,917Jun 30, 2024
SIMPLEX TRADING, LLC0.05%-9,059-8,924-49.62%11,000Jun 30, 2024
TOWER RESEARCH CAPITAL LLC (TRC)0.01%-1,729-2,903-62.67%2,213Jun 30, 2024
NORTHERN TRUST CORP0.25%-44,944-1,542-3.32%57,529,000Jun 30, 2024
WELLS FARGO & COMPANY/MN0.01%-2,650-1,106-29.45%3,392Jun 30, 2024
HM PAYSON & CO----1,000-100.00%-Jun 30, 2024
NEWEDGE ADVISORS, LLC----225-100.00%-Jun 30, 2024
CM MANAGEMENT, LLC0.50%0.11%90,000--115,200Jun 30, 2024
DME CAPITAL MANAGEMENT, LP3.15%0.04%566,130--724,646Jun 30, 2024
PRELUDE CAPITAL MANAGEMENT, LLC0.20%0.00%35,820--45,850Jun 30, 2024
CREEKMUR ASSET MANAGEMENT LLC0.02%0.00%4,440--5,683Jun 30, 2024
BANK OF AMERICA CORP /DE/0.02%-3,5001253.70%4,480Jun 30, 2024
MORGAN STANLEY0.02%-3,30050017.86%4,224Jun 30, 2024
UBS GROUP AG0.06%-11,4222,74931.70%14,620Jun 30, 2024
STATE STREET CORP0.19%-34,4373,60011.67%44,079,000Jun 30, 2024
GROUP ONE TRADING, L.P.0.04%-7,4015,400269.87%9,473,000Jun 30, 2024
GEODE CAPITAL MANAGEMENT, LLC1.02%-183,7366,6453.75%235,217Jun 30, 2024
JONES FINANCIAL COMPANIES LLLP0.04%-7,0007,000100.00%8,960Jun 30, 2024

As of Jun 30 2024, Gain Therapeutics's biggest institutional seller is RAYMOND JAMES & ASSOCIATES. The company sold -0.26M shares of GANX, valued at -.

Institutional New positions

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
TIMELO INVESTMENT MANAGEMENT INC.3.37%0.44%605,288605,288100.00%774,769Jun 30, 2024
ALYESKA INVESTMENT GROUP, L.P.2.50%0.00%450,000450,000100.00%576,000Jun 30, 2024
HOHIMER WEALTH MANAGEMENT, LLC1.84%0.10%330,000330,000100.00%422,400Jun 30, 2024
CABLE CAR CAPITAL LLC0.81%0.20%145,000145,000100.00%185,600Jun 30, 2024
WARBERG ASSET MANAGEMENT LLC0.29%0.01%51,60051,600100.00%65,532Jun 30, 2024
VIRTU FINANCIAL LLC0.15%0.00%27,35627,356100.00%35,000Jun 30, 2024
GILBERT & COOK, INC.0.06%0.00%10,00010,000100.00%12,800Jun 30, 2024
JONES FINANCIAL COMPANIES LLLP0.04%-7,0007,000100.00%8,960Jun 30, 2024

Gain Therapeutics's largest new institutional shareholder by number of shares is TIMELO INVESTMENT MANAGEMENT INC., purchased 605.29K shares, valued at $774.77K, as of undefined.

Institutional Sold Out

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
RAYMOND JAMES & ASSOCIATES----260,019-100.00%-Jun 30, 2024
ROYAL BANK OF CANADA----248,500-100.00%-Jun 30, 2024
HM PAYSON & CO----1,000-100.00%-Jun 30, 2024
NEWEDGE ADVISORS, LLC----225-100.00%-Jun 30, 2024

Gain Therapeutics's largest sold out institutional shareholder by shares sold is RAYMOND JAMES & ASSOCIATES, sold -0.26M shares, valued at -, as of undefined.

Gain Therapeutics Mutual Fund Holders


Name% Total AssetsTotal SharesChange AmountChange %Date
BRIDGEWAY FUNDS INC0.01%30,000-16,100-34.92%Mar 28, 2024
FIDELITY CONCORD STREET TRUST0.00%148,748-389-0.26%Feb 29, 2024
VANGUARD INDEX FUNDS0.00%109,849-47,891-30.36%Mar 31, 2024
SCHWAB CAPITAL TRUST0.00%7,043--Jan 31, 2024
DFA INVESTMENT DIMENSIONS GROUP INC0.00%13,531--Jan 31, 2024
USAA MUTUAL FUNDS TRUST0.00%1,102--Jan 31, 2024
Dimensional ETF Trust0.00%933--Jan 31, 2024
EQ ADVISORS TRUST0.00%2,37444923.32%Mar 31, 2024
iSHARES TRUST0.00%29,9235,41922.11%Mar 31, 2024
JOHN HANCOCK VARIABLE INSURANCE TRUST0.00%238148164.44%Mar 31, 2024

Gain Therapeutics's largest mutual fund holder by % of total assets is "BRIDGEWAY FUNDS INC", owning 30.00K shares, compromising 0.01% of its total assets.

Gain Therapeutics Institutional Ownership Trends


Institutional Holdings Trend

DateHoldingsChange %
30 Jun, 248-73.33%
31 Mar, 243015.38%
31 Dec, 2326-
30 Sep, 2326-3.70%
30 Jun, 232712.50%
31 Mar, 232414.29%
31 Dec, 2221-4.55%
30 Sep, 222237.50%
30 Jun, 2216-
31 Mar, 2216-11.11%
31 Dec, 211838.46%
30 Sep, 21138.33%
30 Jun, 2112-
31 Mar, 2112-

As of 30 Jun 24, 8 institutions are holding Gain Therapeutics's shares, representing a decrease of -73.33% compared to the previous quarter.

Shares Outstanding Trend

DateShares OutstandingChange %
30 Jun, 24820,451-56.07%
31 Mar, 241,867,61520.86%
31 Dec, 231,545,2471.96%
30 Sep, 231,515,52319.55%
30 Jun, 231,267,72210.29%
31 Mar, 231,149,488-4.75%
31 Dec, 221,206,763-0.55%
30 Sep, 221,213,39612.87%
30 Jun, 221,075,072-7.46%
31 Mar, 221,161,73810.04%
31 Dec, 211,055,75518.28%
30 Sep, 21892,606-0.18%
30 Jun, 21894,199-11.13%
31 Mar, 211,006,151-

Gain Therapeutics (GANX) has 820.45K shares outstanding as of 30 Jun 24, down -56.07% compared to the previous quarter.

Institutional Ownership Trend

DateOwnership %Change %
30 Jun, 244.56%3.44%
31 Mar, 2411.52%7.79%
31 Dec, 2312.17%8.13%
30 Sep, 2312.23%10.84%
30 Jun, 2310.62%11.45%
31 Mar, 239.63%9.34%
31 Dec, 2210.16%9.74%
30 Sep, 2210.21%12.48%
30 Jun, 229.05%9.47%
31 Mar, 229.78%9.06%
31 Dec, 2110.39%18.39%
30 Sep, 217.52%13.26%
30 Jun, 217.53%10.49%
31 Mar, 218.47%-

As of 30 Jun 24, Gain Therapeutics is held by 4.56% institutional shareholders, representing a 3.44% growth compared to 31 Mar 24.

Institutional Increased Positions Trend

DateIncreased PositionsChange %
30 Jun, 246-60.00%
31 Mar, 241536.36%
31 Dec, 2311-8.33%
30 Sep, 2312-14.29%
30 Jun, 231455.56%
31 Mar, 23912.50%
31 Dec, 228-38.46%
30 Sep, 221344.44%
30 Jun, 22928.57%
31 Mar, 227-36.36%
31 Dec, 211183.33%
30 Sep, 216-14.29%
30 Jun, 217-41.67%
31 Mar, 2112-

6 institutional shareholders have increased their position in GANX stock as of 30 Jun 24 compared to 15 in the previous quarter (a -60.00% decrease).

Institutional Reduced Positions Trend

DateReduced PositionsChange %
30 Jun, 241-85.71%
31 Mar, 24716.67%
31 Dec, 23620.00%
30 Sep, 23525.00%
30 Jun, 234-33.33%
31 Mar, 236-
31 Dec, 22650.00%
30 Sep, 22433.33%
30 Jun, 223-40.00%
31 Mar, 225400.00%
31 Dec, 211-
30 Sep, 211-50.00%
30 Jun, 212-
31 Mar, 21--

1 institutional shareholders have reduced their position in GANX stock as of 30 Jun 24 compared to 7 in the previous quarter (a -85.71% decrease).

All Institutional Ownership Trend Data

DateHoldingsChange %Shares OutstandingChange %Ownership %Change %Increased PositionsChange %Reduced PositionsChange %
30 Jun, 248-73.33%820,451-56.07%4.56%3.44%6-60.00%1-85.71%
31 Mar, 243015.38%1,867,61520.86%11.52%7.79%1536.36%716.67%
31 Dec, 2326-1,545,2471.96%12.17%8.13%11-8.33%620.00%
30 Sep, 2326-3.70%1,515,52319.55%12.23%10.84%12-14.29%525.00%
30 Jun, 232712.50%1,267,72210.29%10.62%11.45%1455.56%4-33.33%
31 Mar, 232414.29%1,149,488-4.75%9.63%9.34%912.50%6-
31 Dec, 2221-4.55%1,206,763-0.55%10.16%9.74%8-38.46%650.00%
30 Sep, 222237.50%1,213,39612.87%10.21%12.48%1344.44%433.33%
30 Jun, 2216-1,075,072-7.46%9.05%9.47%928.57%3-40.00%
31 Mar, 2216-11.11%1,161,73810.04%9.78%9.06%7-36.36%5400.00%
31 Dec, 211838.46%1,055,75518.28%10.39%18.39%1183.33%1-
30 Sep, 21138.33%892,606-0.18%7.52%13.26%6-14.29%1-50.00%
30 Jun, 2112-894,199-11.13%7.53%10.49%7-41.67%2-
31 Mar, 2112-1,006,151-8.47%-12---

Gain Therapeutics Insider Shareholders Trades


Open Market Insider Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Aug 12, 2024Mack Geneofficer CFO and Interim CEOP-PurchaseBuy14,400$1.01$14.54K14,400
Aug 12, 2024Islam Khaliddirector, officer Executive ChairmanP-PurchaseBuy50,000$1.00$49.94K50,000
Jul 01, 2024RICHMAN ERIC Idirector-P-PurchaseBuy12,000$1.21$14.52K289,629
Jul 01, 2024RICHMAN ERIC Idirector-P-PurchaseBuy5,000$1.23$6.15K277,629
Apr 01, 2024Riley Jeffrey Scottdirector-P-PurchaseBuy30,000$3.86$115.77K30,000

Open Market Insider Buys

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Aug 12, 2024Mack Geneofficer CFO and Interim CEOP-PurchaseBuy14,400$1.01$14.54K14,400
Aug 12, 2024Islam Khaliddirector, officer Executive ChairmanP-PurchaseBuy50,000$1.00$49.94K50,000
Jul 01, 2024RICHMAN ERIC Idirector-P-PurchaseBuy12,000$1.21$14.52K289,629
Jul 01, 2024RICHMAN ERIC Idirector-P-PurchaseBuy5,000$1.23$6.15K277,629
Apr 01, 2024Riley Jeffrey Scottdirector-P-PurchaseBuy30,000$3.86$115.77K30,000

Insider Sells

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Mar 28, 2024Alder Matthiasdirector, officer Chief Executive OfficerM-ExemptSell18,750--56,250
Mar 28, 2024Alder Matthiasdirector, officer Chief Executive OfficerF-InKindSell6,085$4.06$24.71K21,140
Mar 28, 2024Alder Matthiasdirector, officer Chief Executive OfficerM-ExemptSell825--8,250

All Insider Owners Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Aug 12, 2024Mack Geneofficer CFO and Interim CEOP-PurchaseBuy14,400$1.01$14.54K14,400
Aug 12, 2024Islam Khaliddirector, officer Executive ChairmanP-PurchaseBuy50,000$1.00$49.94K50,000
Jul 01, 2024RICHMAN ERIC Idirector-P-PurchaseBuy12,000$1.21$14.52K289,629
Jul 01, 2024RICHMAN ERIC Idirector-P-PurchaseBuy5,000$1.23$6.15K277,629
Jun 26, 2024Islam Khaliddirector-A-AwardBuy15,000$1.29$19.35K15,000
Jun 26, 2024Melincoff Gwen Adirector-A-AwardBuy15,000$1.29$19.35K15,000
Jun 26, 2024HASLER HANS PETERdirector-A-AwardBuy15,000$1.29$19.35K15,000
Jun 26, 2024Nicaise Claudedirector-A-AwardBuy15,000$1.29$19.35K15,000
Jun 26, 2024RICHMAN ERIC Idirector-A-AwardBuy15,000$1.29$19.35K15,000
Jun 26, 2024GOLDSTEIN DOV A MDdirector-A-AwardBuy15,000$1.29$19.35K15,000
Jun 26, 2024Riley Jeffrey Scottdirector-A-AwardBuy15,000$1.29$19.35K15,000
Apr 08, 2024Mack Geneofficer Chief Financial OfficerA-AwardBuy200,000$3.56$712.00K200,000
Apr 08, 2024Mack Geneofficer-Buy----
Apr 01, 2024Riley Jeffrey Scottdirector-P-PurchaseBuy30,000$3.86$115.77K30,000
Mar 28, 2024Alder Matthiasdirector, officer Chief Executive OfficerM-ExemptSell18,750--56,250
Mar 28, 2024Alder Matthiasdirector, officer Chief Executive OfficerM-ExemptBuy637--27,225
Mar 28, 2024Alder Matthiasdirector, officer Chief Executive OfficerM-ExemptBuy825--26,588
Mar 28, 2024Alder Matthiasdirector, officer Chief Executive OfficerM-ExemptBuy18,750--25,763
Mar 28, 2024Alder Matthiasdirector, officer Chief Executive OfficerF-InKindSell6,085$4.06$24.71K21,140
Mar 28, 2024Alder Matthiasdirector, officer Chief Executive OfficerM-ExemptSell825--8,250

The last insider sell of Gain Therapeutics's stock was made by Alder Matthias on Mar 28 2024, selling 18,750 shares at - per share (valued at -). The last insider buy of GANX was made by Mack Gene on Aug 12 2024, buying 14,400 shares at $1.01 per share (worth $14.54K).

Gain Therapeutics Insider Ownership Trends


All Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q3 20242--
Q2 20248--
Q1 202464150.00%
Q4 20232450.00%
Q3 202333100.00%
Q2 20238--
Q1 20235--
Q4 2022-1-
Q3 20227--
Q2 20225--
Q4 20211--
Q3 20212--
Q1 2021-10-

2 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by Gain Therapeutics's insiders, as of Q3 2024.

Open Market Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q3 20242--
Q2 2024---
Q1 20241--
Q4 2023-2-
Q3 2023---
Q2 2023---
Q1 2023---
Q4 2022---
Q3 2022---
Q2 20225--
Q4 2021---
Q3 20211--
Q1 2021---

As of Q3 2024, Insider owners conducted 2 open market buy trades and 0 open market sell trades of Gain Therapeutics's stocks.

Gain Therapeutics Peer Ownership


TickerCompany
CUECue Biopharma, Inc.
CYTCyteir Therapeutics, Inc.
INBXInhibrx Biosciences, Inc.
CSBRChampions Oncology, Inc.
BIVIBioVie Inc.
LTRNLantern Pharma Inc.
MNOVMediciNova, Inc.
NAMSNewAmsterdam Pharma Company N.V.
INABIN8bio, Inc.
TFFPTFF Pharmaceuticals, Inc.
ANEBAnebulo Pharmaceuticals, Inc.
MOLNMolecular Partners AG
LIFEaTyr Pharma, Inc.
CELCCelcuity Inc.
MACKMerrimack Pharmaceuticals, Inc.
ELVNEnliven Therapeutics, Inc.
ELYMEliem Therapeutics, Inc.

GANX Ownership FAQ


Gain Therapeutics is owned by institutional shareholders (4.56%), insiders (5.09%), and public (90.34%). The largest institutional shareholder of Gain Therapeutics is TIMELO INVESTMENT MANAGEMENT INC. (3.37% of total shares) and the top mutual fund owner is BRIDGEWAY FUNDS INC (0.01% of total shares).

Gain Therapeutics's major institutional shareholders are TIMELO INVESTMENT MANAGEMENT INC., DME CAPITAL MANAGEMENT, LP, ALYESKA INVESTMENT GROUP, L.P., HOHIMER WEALTH MANAGEMENT, LLC, and GEODE CAPITAL MANAGEMENT, LLC. The top five shareholders own together 11.88% of the company's share outstanding.

As of Jun 2024, there are 8 institutional shareholders of Gain Therapeutics.

TIMELO INVESTMENT MANAGEMENT INC owns 605.29K shares of Gain Therapeutics, representing 3.37% of the company's total shares outstanding, valued at $774.77K (as of Jun 2024).

As of Jun 2024, DME CAPITAL MANAGEMENT, LP holds 566.13K shares of Gain Therapeutics (GANX), compromising 3.15% of the company, valued at $724.65K.

ALYESKA INVESTMENT GROUP, L.P is the third largest holder of Gain Therapeutics. The company owns 450K of the company's shares outstanding (worth $576K).